Across TCGA pan-cancer cohorts, BTBD8 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated BTBD8 data layer compared with 28 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher BTBD8 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated BTBD8 expression acts as an unfavorable survival marker, although some lineages such as UCEC and GBM show a favorable association.

UCEC, LSCC, and GBM are the cancer types where BTBD8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Tertile	All	0.942	0.680	.004	12	view →
LSCC	DFS	Median	All	0.601	0.810	.021	11	view →
GBM	DFS	Quartile	All	0.856	0.512	<.001	6	view →
CCRCC	OS	Tertile	III,IV	0.814	0.476	.009	6	view →
PDAC	DFS	Tertile	All	0.692	0.852	.037	4	view →
HNSC	DFS	Tertile	III,IV	0.283	0.692	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

Exploration

Same gene, other analysis: BTBD8 tumor-vs-normal RNA expression · all BTBD8 data types